Our Approach

Fibrocor uses state of the art genomics platform married to a 20 year biobank repository consisting of diseased tissues to identify and validate new targets.

Our Team

Fibrocor has recruited a top notch drug discovery and world class translational biology team consisting of the following:

Dr. Richard Gilbert

Endocrinologist, clinician-scientist. Canada Research Chair in Diabetes Complications Co-founder of Fibrotech- Acquired by Shire in 2014

Dr. Richard Gilbert

Chief Scientific Officer

Dr. Darren Yuen

Repository of clinical samples from patients with various stages of kidney disease

Dr. Darren Yuen

Transplantation nephrologist, clinician-scientist

Dr. Jeff Wrana

Focus on protein interaction networks in disease prognosis an treatment.

Dr. Jeff Wrana

World renowned researcher in cell signaling pathways.

Mr. Mark Steedman

Mark brings 15 years of experience in building successful companies in the Toronto area.

Mr. Mark Steedman

President and CEO

Our Technology

Target Discovery Engine

Fibrocor has the ability to investigate tissue samples from fresh frozen or formalin fixed preparation with a state of the art genomics platform that includes RNA Sequencing, KO models, and CRISPR Cas to identify targets that are linked to specific clinical populations that suffer from fibrosis. This engine has already yielded several promising targets in renal, lung, liver of which are areasof severe unmet need in fibrosis.

The Fibrocor Advantage

Unlike other biobank companies, the company is focused on mining the longitudinal data for new fibrotic targets associated with specific clinical outcomes. Fibrocor takes advantage of the single payer system in Ontario to track patient outcomes over time, and together with the powerful genomics platform can readily identify specific clinical populations (fast responders, slow responders, no responders, etc.) that are linked to specific genotypes.

Pipeline

Lead Program (FIB 656)

Fibrocor’s lead program is focused on a small molecule inhibitor of DDR, a target that is implicated in kidney fibrosis. Proof of concept studies in mice models are due Q2 2018, with IND enabling studies set to begin in Q1 2019. This product was licensed to Galapagos (NASDAQ: GLPG) in 2018.

Two putative targets have been identified from the longitudinal data, and it is anticipated that med chem activities will begin in Q4 2018

Second Program (FIB 911)

Fibrocor will seek to closely follow the Renal Fibrosis indication with a similar small molecule approach in liver fibrosis. It is anticipated that first in human studies will be initiated in Q3 2020

Pipeline Programs (FIB 204/205)

The biobank interrogation has yielded two putative tyrosine kinase targets worthy of further investigation. A full med chem / phys chem program is slated to be initiated in 2019.

Fibrocor Therapeutics - Development Timelines

Board of Directors

Rafi Hofstein

Dr. Raphael (Rafi) Hofstein joined MaRS Innovation as President and CEO in June 2009. He is currently member of the board of directors of Life Science Ontario and of Clinical Trials Ontario, as well as a member of the Organizing Committee of the Public Policy Forum on Venture Capital and Innovation…

Rafi Hofstein

MaRS Innovation

William Newsome III

William Newsome III

Evotec

Mr. Mark Steedman

Mark brings 15 years of experience in building successful companies in the Toronto area.

Mr. Mark Steedman

President and CEO

Cynthia LaVoie

Dr. Lavoie is a seasoned investment professional with fifteen years’ experience in venture capital. She is also an accomplished academic with a strong scientific background having spent an additional ten years in R&D in research institutes and life science firms. 

Cynthia LaVoie

AllosteRX Capital

Dr. Richard Gilbert

Endocrinologist, clinician-scientist. Canada Research Chair in Diabetes Complications Co-founder of Fibrotech- Acquired by Shire in 2014

Dr. Richard Gilbert

Chief Scientific Officer

Darlene Homonko

Darlene Homonko

Mt. Sinai Hospital

Latest News

Contact Us

Fibrocor Therapeutics L.P.
661 University Ave, Suite 465
Toronto Ontario Canada
M5G 1M1

℅ Mark Steedman
647 978 3697